Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma

Journal of Investigative Dermatology

Volumn 106, Issue 6, 1996, Pages 1163-1168

  Bonnekoh, Bernd ^a,c   Greenhalgh, David A ^a,d   Bundman, Donnie S ^a   Kosai, Ken Ichiro ^a   Chen, Shu Hsia ^a,b   Finegold, Milton J ^a   Krieg, Thomas ^c   Woo, Savio L C ^a,b   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

adenovirus; cancer; gene therapy; nude mice

Indexed keywords

GANCICLOVIR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029946085     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12347786     Document Type: Article

References (43)

1. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen S-H, Woo SLC, Roop DR: Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol 104:313-317, 1995
2. Bonnekoh B, Wevers A, Geisel J, Rasokat H, Mahrle G: Antiproliferative potential of zidovudine in human keratinocyte cultures. J Am Acad Dermatol 25:483-490, 1991
3. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771, 1988
4. Chen S-H, Chen XHL, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SLC: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577-2581, 1995
5. Chen S-H, Shine D, Goodman JC, Grossman RG, Woo SLC: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91:3054-3057, 1994
6. Crowley NJ, Seigler HF: Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 9:273-278, 1993
7. Crystal RG: The gene as the drug. Nature Med 1:15-17, 1995
8. Faulds D, Heel RC: Ganciclovir - a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597-638, 1990
9. Fidler IJ: Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35:218-224, 1975
10. Fidler IJ: The biology of melanoma metastasis. In: Balch CM (ed.). Cutaneous Melanoma, J B Lippincott, Philadelphia, 1992, pp 112-129
11. Foa R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gansbacher B: Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun 13:65-75, 1994
12. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283, 1993
13. Fujiwara T, Grimm EA, Roth JA: Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 6:96-105, 1994
14. Glass AG, Hoover RN: The emerging epidemic of melanoma and squamous cell skin cancer. J Am Med Assoc 262:2097-2100, 1989
15. Gleason JF, Bhartia PK, Herman JR, McPeters R, Newman P, Stokarski RS, Flynn L, Labow G, Larko D, Seftor C, Wellemeyer C, Komhyr WD, Miller AJ, Planet W: Record low global ozone in 1992. Science 260:523-526, 1993
16. Graham FL, Prevec L: Manipulation of adenovirus vectors. In: EJ Murray (ed.). Methods in Molecular Biology, Vol. 7, Humana Press, Totowa, NJ, 1991, pp 109-128
17. Greber UF, Willetts M, Webster P, Helenius A: Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-486, 1993
18. Hart IR, Vile RG: Targeted therapy for melanoma. Curr Opin Oncol 6:221-225, 1994
19. Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD: Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 68:5239-5246, 1994
20. Huang S, Endo RI, Nemerow GR: Upregulation of integrins αvβ3 and αvβ5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 69:2257-2263, 1995
21. Irie RF, DeNunzio FD: Immunotherapy of melanoma: current status and prospects for the future. J Dermatol 20:65-73, 1993
22. Johnson TM, Smith JW, Nelson BR, Chang A: Current therapy for cutaneous melanoma. J Am Acad Dermatol 32:689-707, 1995
23. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 3:499-503, 1993
24. Kozlowski JM, Hart IR, Fidler IJ, Hanna N: A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mite. J Natl Cancer Inst 72:913-917, 1984
25. MacGregor GR, Caskey CT: Construction of plasmids that express E. coli β-galactosidase in mammalian tells. Nucleic Acids Res 17:2365-2372, 1989
26. Mathias P, Wickham TJ, Moore M, Nemerow G: Multiple adenovirus serotypes use αv integrins for infection. J Virol 68:6811-6814, 1994
27. Matthews T, Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10:S490-S494, 1988
28. Moolten FL: Tumor themosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281, 1986
29. Porgador A, Feldman M, Eisenbach E: Immunotherapy of tumor metastasis via gene therapy. Nat Immun 13:113-130, 1994
30. Rankin EM: Scientific aspects of gene therapy in melanoma Curr Opin Oncol 7:192-196, 1995
31. Rigel DS: Epidemiology and prognostic factors in malignant melanoma. Ann Plast Surg 28:7-8, 1992
32. Rigel DS, Kopf AW, Friedman RJ: The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol 17:1050-1053, 1987
33. Rosenthal FM, Zier KS, Gansbacher B: Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity. Curr Opin Oncol 6:611-615, 1994
34. Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda SM, Kaiser LR: Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg 109:626-631, 1995
35. Staroselsky AH, Pathak S, Chernajovsky Y, Tucker SL, Fidler IJ: Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Res 51:6292-6298, 1991
36. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P: Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 90:626-630, 1992
37. Teramoto S, Johnson LG, Huang W, Leigh MW, Boucher RC: Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells. Hum Gene Ther 6: 1045-1053, 1995
38. Vile R, Russell SJ: Gene transfer technologies for the gene therapy of cancer. Gene Therapy 1:88-98, 1994
39. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR: Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 127:257-264, 1994
40. 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319, 1993
41. Wu JK, Cano WG, Meylaerts SAG, Qui P, Vrionis F, Cherington V: Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35:1094-1103, 1994
42. Yang Y, Xiang Z, Ertl HCJ, Wilson JM: Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination ot recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 92:7257-7261, 1995
43. Zatloukal K, Schneeberger A, Berger M, Koszik F, Schmidt W, Wagner E, Cotten M, Buschle M, Maass G, Stingl G: Genetic modification of cells by receptor-mediated adenovirus-augmented gene delivery: a new approach for immunotherapy of cancer. Verh Dtsch Ges Pathol 78:171-176, 1994